-
Je něco špatně v tomto záznamu ?
Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer
D. D'Andrea, F. Soria, AJ. Grotenhuis, EK. Cha, N. Malats, S. Di Stasi, S. Joniau, T. Cai, BWG. van Rhijn, J. Irani, J. Karnes, J. Varkarakis, J. Baniel, J. Palou, M. Babjuk, M. Spahn, P. Ardelt, R. Colombo, V. Serretta, G. Dalbagni, P. Gontero,...
Jazyk angličtina Země Německo
Typ dokumentu srovnávací studie, časopisecké články
Grantová podpora
P30 CA008748
NCI NIH HHS - United States
- MeSH
- adjuvancia imunologická aplikace a dávkování MeSH
- aplikace intravezikální MeSH
- BCG vakcína aplikace a dávkování MeSH
- imunoterapie * MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory močového měchýře farmakoterapie patologie MeSH
- retrospektivní studie MeSH
- senioři MeSH
- sexuální faktory MeSH
- stupeň nádoru MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
PURPOSE: To investigate the association of patients' sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette-Guérin (BCG) for T1G3/HG urinary bladder cancer (UBC). MATERIALS AND METHODS: We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing data using multiple imputations and adjusted for covariate imbalance between males and females using inverse probability weighting (IPW). Crude and IPW-adjusted Cox regression analyses were used to estimate the hazard ratios (HR) with their 95% confidence intervals (CI) for the association of patients' sex with HG-recurrence and disease progression. RESULTS: A total of 2170 (82%) males and 465 (18%) females were available for analysis. Overall, 1090 (50%) males and 244 (52%) females experienced recurrence, and 391 (18%) males and 104 (22%) females experienced disease progression. On IPW-adjusted Cox regression analyses, female sex was associated with disease progression (HR 1.25, 95%CI 1.01-1.56, p = 0.04) but not with recurrence (HR 1.06, 95%CI 0.92-1.22, p = 0.41). A total of 1056 patients were treated with adequate BCG. In these patients, on IPW-adjusted Cox regression analyses, patients' sex was not associated with recurrence (HR 0.99, 95%CI 0.80-1.24, p = 0.96), HG-recurrence (HR 1.00, 95%CI 0.78-1.29, p = 0.99) or disease progression (HR 1.12, 95%CI 0.78-1.60, p = 0.55). CONCLUSION: Our analysis generates the hypothesis of a differential response to BCG between males and females if not adequately treated. Further studies should focus on sex-based differences in innate and adaptive immune system and their association with BCG response.
Departement of Urology Università Vita Salute Ospedale S Raffaele Milan Italy
Department of Surgical Oncological and Stomatological Sciences University of Palermo Palermo Italy
Department of Translational Research and New Technologies University of Pisa Pisa Italy
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Academic Hospital Uppsala University Uppsala Sweden
Department of Urology CHU de Reims Reims France
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Fundacio Puigvert University of Barcelona Barcelona Spain
Department of Urology Mayo Clinic Rochester MN USA
Department of Urology Memorial Sloan Kettering Cancer Center New York NY USA
Department of Urology Motol Hospital University of Praha Prague Czech Republic
Department of Urology Policlinico Tor Vergata University of Rome Rome Italy
Department of Urology Rabin Medical Centre Tel Aviv Israel
Department of Urology Radboud University Nijmegen Medical Centre Nijmegen The Netherlands
Department of Urology Santa Chiara Hospital Trento Italy
Department of Urology Sismanoglio Hospital University of Athens Athens Greece
Department of Urology Universitätsklinik Freiburg Freiburg Germany
Department of Urology University Hospital of Wuerzburg Wuertzburg Germany
Department of Urology University of Jordan Amman Jordan
Department of Urology Weill Medical College of Cornell University New York NY USA
European Association of Urology Non Muscle Invasive Bladder Cancer Guidelines Panel Brussels Belgium
European Association of Urology Research Foundation Arnhem The Netherlands
Genetic and Molecular Epidemiology Group Spanish National Cancer Research Centre Madrid Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012276
- 003
- CZ-PrNML
- 005
- 20220506130218.0
- 007
- ta
- 008
- 220425s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-021-03653-1 $2 doi
- 035 __
- $a (PubMed)33713162
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. dd.dandrea@gmail.com $1 https://orcid.org/0000000316251077
- 245 10
- $a Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer / $c D. D'Andrea, F. Soria, AJ. Grotenhuis, EK. Cha, N. Malats, S. Di Stasi, S. Joniau, T. Cai, BWG. van Rhijn, J. Irani, J. Karnes, J. Varkarakis, J. Baniel, J. Palou, M. Babjuk, M. Spahn, P. Ardelt, R. Colombo, V. Serretta, G. Dalbagni, P. Gontero, R. Bartoletti, S. Larré, PU. Malmstrom, R. Sylvester, SF. Shariat
- 520 9_
- $a PURPOSE: To investigate the association of patients' sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette-Guérin (BCG) for T1G3/HG urinary bladder cancer (UBC). MATERIALS AND METHODS: We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing data using multiple imputations and adjusted for covariate imbalance between males and females using inverse probability weighting (IPW). Crude and IPW-adjusted Cox regression analyses were used to estimate the hazard ratios (HR) with their 95% confidence intervals (CI) for the association of patients' sex with HG-recurrence and disease progression. RESULTS: A total of 2170 (82%) males and 465 (18%) females were available for analysis. Overall, 1090 (50%) males and 244 (52%) females experienced recurrence, and 391 (18%) males and 104 (22%) females experienced disease progression. On IPW-adjusted Cox regression analyses, female sex was associated with disease progression (HR 1.25, 95%CI 1.01-1.56, p = 0.04) but not with recurrence (HR 1.06, 95%CI 0.92-1.22, p = 0.41). A total of 1056 patients were treated with adequate BCG. In these patients, on IPW-adjusted Cox regression analyses, patients' sex was not associated with recurrence (HR 0.99, 95%CI 0.80-1.24, p = 0.96), HG-recurrence (HR 1.00, 95%CI 0.78-1.29, p = 0.99) or disease progression (HR 1.12, 95%CI 0.78-1.60, p = 0.55). CONCLUSION: Our analysis generates the hypothesis of a differential response to BCG between males and females if not adequately treated. Further studies should focus on sex-based differences in innate and adaptive immune system and their association with BCG response.
- 650 _2
- $a adjuvancia imunologická $x aplikace a dávkování $7 D000276
- 650 _2
- $a aplikace intravezikální $7 D000283
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a BCG vakcína $x aplikace a dávkování $7 D001500
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a imunoterapie $7 D007167
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a sexuální faktory $7 D012737
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nádory močového měchýře $x farmakoterapie $x patologie $7 D001749
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Soria, Francesco $u Division of Urology, University of the Studies of Turin, AOU Città Della Salute e Della Scienza di Torino, Presidio Molinette, Turin, Italy
- 700 1_
- $a Grotenhuis, Anne J $u Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
- 700 1_
- $a Cha, Eugene K $u Department of Urology, Weill Medical College of Cornell, University, New York, NY, USA $u Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Malats, Nuria $u Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
- 700 1_
- $a Di Stasi, Savino $u Department of Urology, Policlinico Tor Vergata-University of Rome, Rome, Italy
- 700 1_
- $a Joniau, Steven $u Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Cai, Tommaso $u Department of Urology, Santa Chiara Hospital, Trento, Italy
- 700 1_
- $a van Rhijn, Bas W G $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Irani, Jaques $u Department of Urology, Centre Hospitalier Universitaire La Milétrie, University of Poitiers, Poitiers, France
- 700 1_
- $a Karnes, Jeffrey $u Department of Urology, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Varkarakis, John $u Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece
- 700 1_
- $a Baniel, Jack $u Department of Urology, Rabin Medical Centre, Tel Aviv, Israel
- 700 1_
- $a Palou, Joan $u Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain
- 700 1_
- $a Babjuk, Marek $u Department of Urology, Motol Hospital, University of Praha, Prague, Czech Republic
- 700 1_
- $a Spahn, Martin $u Department of Urology, University Hospital of Wuerzburg, Wuertzburg, Germany
- 700 1_
- $a Ardelt, Peter $u Department of Urology, Universitätsklinik Freiburg, Freiburg, Germany
- 700 1_
- $a Colombo, Renzo $u Departement of Urology, Università Vita Salute, Ospedale S. Raffaele, Milan, Italy
- 700 1_
- $a Serretta, Vincenzo $u Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy
- 700 1_
- $a Dalbagni, Guido $u Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Gontero, Paolo $u Division of Urology, University of the Studies of Turin, AOU Città Della Salute e Della Scienza di Torino, Presidio Molinette, Turin, Italy
- 700 1_
- $a Bartoletti, Riccardo $u Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy
- 700 1_
- $a Larré, Stephane $u Department of Urology, CHU de Reims, Reims, France
- 700 1_
- $a Malmstrom, Per-Uno $u Department of Urology, Academic Hospital, Uppsala University, Uppsala, Sweden
- 700 1_
- $a Sylvester, Richard $u European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Brussels, Belgium
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Medical College of Cornell, University, New York, NY, USA $u Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Department of Urology, University of Jordan, Amman, Jordan $u European Association of Urology Research Foundation, Arnhem, The Netherlands
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 39, č. 9 (2021), s. 3337-3344
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33713162 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130210 $b ABA008
- 999 __
- $a ok $b bmc $g 1789737 $s 1163477
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 39 $c 9 $d 3337-3344 $e 20210313 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- GRA __
- $a P30 CA008748 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20220425
